» Articles » PMID: 20831290

Value-based Approaches to Healthcare Systems and Pharmacoeconomics Requirements in Asia: South Korea, Taiwan, Thailand and Japan

Overview
Specialty Pharmacology
Date 2010 Sep 14
PMID 20831290
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Asian healthcare systems are very diverse, representing cultures, political systems and economies from more than 30 countries with varying histories. Despite the diversity in the region, there has been enormous growth in health economics and outcomes research since the beginning of the 21st century. Whilst Japan has seen very limited use of health technology assessment (HTA), South Korea, Taiwan and Thailand have had remarkable success in establishing government agencies for HTA, employing HTA concepts from the UK National Institute for Health and Clinical Excellence (NICE). These three countries are driven by the following common factors: (i) a desire to establish universal healthcare insurance coverage in their respective nations; (ii) the need for rational allocation of scarce resources; (iii) a desire for government to provide leadership in HTA; and (iv) availability of HTA professionals and faculties through international networks. The HTA models introduced by these three countries are both similar to and different from those of HTA agencies in Europe, but might work well as examples for other countries in the region.

Citing Articles

The State of Pharmacoeconomics Education in the Doctor of Pharmacy Curriculum amid the Changing Face of Pharmacy Practice.

Adunlin G, Skiera J, Cupp C, Ali A, Afeli S Healthcare (Basel). 2023; 11(22).

PMID: 37998415 PMC: 10671399. DOI: 10.3390/healthcare11222923.


A SWOT analysis of the development of health technology assessment in Iran.

Behzadifar M, Ghanbari M, Azari S, Bakhtiari A, Rahimi S, Ehsanzadeh S PLoS One. 2023; 18(3):e0283663.

PMID: 36996128 PMC: 10062657. DOI: 10.1371/journal.pone.0283663.


Which multi-attribute utility instruments are recommended for use in cost-utility analysis? A review of national health technology assessment (HTA) guidelines.

Kennedy-Martin M, Slaap B, Herdman M, van Reenen M, Kennedy-Martin T, Greiner W Eur J Health Econ. 2020; 21(8):1245-1257.

PMID: 32514643 PMC: 7561556. DOI: 10.1007/s10198-020-01195-8.


Value-based healthcare translated: a complementary view of implementation.

Collden C, Hellstrom A BMC Health Serv Res. 2018; 18(1):681.

PMID: 30176866 PMC: 6122703. DOI: 10.1186/s12913-018-3488-9.


Cost-Effectiveness Thresholds: the Past, the Present and the Future.

Thokala P, Ochalek J, Leech A, Tong T Pharmacoeconomics. 2018; 36(5):509-522.

PMID: 29427072 DOI: 10.1007/s40273-017-0606-1.


References
1.
Jirawattanapisal T, Kingkaew P, Lee T, Yang M . Evidence-based decision-making in Asia-Pacific with rapidly changing health-care systems: Thailand, South Korea, and Taiwan. Value Health. 2010; 12 Suppl 3:S4-11. DOI: 10.1111/j.1524-4733.2009.00620.x. View

2.
Cutler D . Will the cost curve bend, even without reform?. N Engl J Med. 2009; 361(15):1424-5. DOI: 10.1056/NEJMp0907417. View

3.
Weinstein M, Skinner J . Comparative effectiveness and health care spending--implications for reform. N Engl J Med. 2010; 362(5):460-5. PMC: 2819079. DOI: 10.1056/NEJMsb0911104. View

4.
Martelli F, La Torre G, Di Ghionno E, Staniscia T, Neroni M, Cicchetti A . Health technology assessment agencies: an international overview of organizational aspects. Int J Technol Assess Health Care. 2007; 23(4):414-24. DOI: 10.1017/S026646230707064X. View

5.
McGhan W, Al M, Doshi J, Kamae I, Marx S, Rindress D . The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report. Value Health. 2009; 12(8):1086-99. DOI: 10.1111/j.1524-4733.2009.00605.x. View